Researchers to Report Progress Using Metabolomic Profiling of Biomarkers As Assisted Reproductive Procedure in Assessing Embryo Viability for In Vitro Fertilization
Molecular Biometrics (MB), a privately held metabolomics company, today announced that researchers will present results of three clinical studies investigating the use of ViaTest(TM)-E, the Company’s non-invasive platform designed to assess embryo and gamete viability in IVF. ViaTest-E was developed using Molecular Biometrics’ proprietary technology of biospectroscopy-based metabolomics (BSM(TM)). The results of these studies will be presented at The 23rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Lyon, France (July 1 – 4, 2007). Molecular Biometrics will also exhibit at ESHRE, where it will unveil and demonstrate the Company’s proprietary BSM System prototype.
James Posillico, Ph.D., President and CEO of Molecular Biometrics commented, “Molecular Biometrics plans to offer IVF practitioners a rapid, objective method for assessing embryo viability that overcomes limitations associated with the current clinical practice of morphological examination. The selection of viable embryos is central to successful outcomes in IVF. The three studies to be presented at the ESHRE conference illustrate the accuracy of the Company’s non-invasive metabolomic methodology compared to morphology, and will further support the commercialization of Molecular Biometrics’ ViaTest-E technology.”
Molecular Biometrics Presentations at ESHRE (Abstracts available upon request):
In a podium presentation (0077 – Session 19: PGS/Embryo Selection Room: Pasteur Auditorium), Principal Investigators Carlijn Vergouw, M.Sc. and Dr. C.B. Lambalk (et. al.) of the Medical Centre, Reproductive Medicine, Amsterdam, the Netherlands, will present findings of a study titled, Near Infrared Spectroscopy as a tool to predict embryo viability: a novel, non-invasive method for embryo selection. This presentation will take place July 2, 2007 from 3:15 PM to 4:30 PM.
In a poster presentation (# P 425) Principal Investigator, B. Behr (et. al.) of Stanford University, Department of Obstetrics and Gynecology, Stanford California, will present findings of a study titled, Identification of unique biomarkers of human oocyte maturation by non-invasive metabolomic profiling.
In a podium presentation (0025 Session 05 – Embryology Room – Forum 2), Principal Investigator C.D. Skinner (et. al.) of Concordia University, Quebec, will present findings of a study titled, Albumin modification in culture media as a surrogate marker that is predictive of embryo viability. This presentation will take place, July 2nd, 2007 from 10:00 AM to 11:30 AM.
Molecular Biometrics’ ViaTest-E is a non-invasive, point-of-care system that targets in vitro biomarkers of oxidative metabolism (OM) that are indicative of embryo viability. Complex interactions between the pro-oxidants and antioxidants are crucial in the maintenance of normal intracellular homeostasis. An imbalance in these reactions results in OM, which is known to affect the quality of spermatozoa, eggs and embryos.
The company’s cost-effective ViaTest-E System enables rapid identification and simultaneous analysis of multiple small molecule biomarkers of OM in a single sample. This analysis is expected to lead to the fast, accurate detection of viable embryos of high reproductive potential. Single use, disposable sample cells are used in conjunction with the Company’s proprietary instrumentation. The Company’s metabolomics platform has also been applied to multiple other therapeutic applications, as well as in pharmacodiagnostics for drug discovery and development.
For more information about ESHRE visit http://www.eshre.com/emc.asp
Based in Chester, New Jersey, with a research and development facility in Montreal, Quebec, Molecular Biometrics, LLC is a privately held metabolomics company developing highly specific and sensitive analytical methodologies for molecular diagnostic and monitoring applications in medicine, and for drug discovery and development through pharmacodiagnostics based on its novel technology platform of metabolomics. For more information, please visit http://www.molecularbiometrics.com/.
Contact: Bryan P. Murphy LaVoie Group 978.745.4200 x 105 Email Contact
SOURCE: Molecular Biometrics